Omaveloxolone (Skyclarys): Side Effect Management and Clinical Guide for Friedreich’s Ataxia

　　1.Overview of Omaveloxolone

　　Omaveloxolone(brand name Skyclarys)is a first-in-class Nrf2 activator indicated for Friedreich’s Ataxia(FA).By activating the Nrf2 pathway,it enhances antioxidant responses and mitochondrial function to slow neurodegeneration.Approved by the FDA in 2023,it remains unavailable in many regions,with an estimated overseas cost of approximately$27,000 per month.

　　2.Common Adverse Reactions

　　Data from the MOXIe trial show common side effects(≥10%)are mostly Grade 1-2:headache(35%),nausea(28%),fatigue(22%),diarrhea(18%),abdominal pain(15%),elevated transaminases(20%),and back pain(12%).

　　3.Hepatotoxicity Management

　　Hepatotoxicity is the primary safety concern.

　　Monitoring:​Baseline LFTs,then at months 1,3,6,and every 6 months thereafter.

　　Management:

　　ALT≤3x ULN:Continue therapy with increased monitoring.

　　ALT 3-5x ULN:Hold dosing;resume at same dose once≤2x ULN.

　　ALT>5x ULN or jaundice:Permanent discontinuation.

　　Warnings:​Avoid concomitant use with other hepatotoxic drugs(e.g.,high-dose acetaminophen>2g/day,isoniazid).

　　4.Managing Other Side Effects

　　GI Issues:​Take with food.Use metoclopramide/ondansetron for nausea and loperamide/smectite for diarrhea.Severe diarrhea(>6 episodes/day)requires suspension.

　　Headache:​Manage with acetaminophen or ibuprofen.Consider propranolol prophylaxis if frequent.Rule out reversible cerebral vasoconstriction syndrome if neurological symptoms occur.

　　Fatigue/Musculoskeletal:​Dose reduction(150mg to 100mg)may be considered for persistent fatigue.NSAIDs or physical therapy can address back/joint pain.

　　5.Drug Interactions&Special Populations

　　Metabolized via CYP3A4.Avoid​strong inhibitors(clarithromycin,itraconazole,grapefruit)which raise levels,and avoid​strong inducers(rifampin,carbamazepine)which lower efficacy.Not recommended for moderate hepatic impairment or pregnancy.No dose adjustment needed for renal impairment.

　　6.Patient Education

　　Therapy aims to slow progression(mFARS improvement of~2.4 points at 48 weeks).Patients should assess financial sustainability and inquire about manufacturer assistance programs(US/EU residency often required).Patients in non-approved regions may seek enrollment in future clinical trials.